Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug ...
Patients with rare diseases in India, like Saifullah Khalidi with spinal muscular atrophy (SMA), struggle to afford ...
Roche’s first hot ‘kūmara’Brian Roche begins his job as public service commissioner this week, and the appointment of an ...
Ten agonising days after he was last seen alive, the family of missing Wexford man Brandon Roche were granted some small ...
Roche, a Swiss multinational healthcare company, is seeking a permanent injunction against Natco Pharma to prevent the introduction of a generic version of Risdiplam, a Spinal Muscular Atrophy (SMA) ...
Patient advocates push for generic drug production to treat rare diseases, facing patent barriers and high costs.
Mark Laroche, president and CEO of the YOW Authority, has been named Newsmaker of the Year for 2024 by the Ottawa Business ...
A 3,500-square-foot Starbucks has opened on the site that was once home to pharmaceutical giant Hoffmann-La Roche in Clifton.
The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened ...
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...
Roche's bid to block a generic SMA drug risks public health by limiting affordable access, say patient groups, highlighting high costs and patent issues.
Drug cost analysis expert reveals that the life-saving drug Risdiplam, used to treat the rare genetic disease SMA, could ...